Resistance to imatinib can be divided into primary resistance, in which patients show lack of efficacy to this tyrosine kinase inhibitor (TKI) from the start

Simonsson B, Gedde-Dahl T, Markevarn B, Remes K, Stentoft J, Almqvist A, Bjoreman M, Floegard M, Hallman H, Koskenvesa P, Lindblom A, Malm C, Mustjoki S, Myhr-Eriksson K, Rasanen

Treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients who harbour the BCR- ABL T315I mutation with subcutaneous omacetaxine results in im- proved survival compared

Abbreviations: ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; AML, acute myeloid leukemia; mAb, monoclonal antibodies,

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; DLBCL, diffuse large B-cell

ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; CBF: core binding factor; CLL: chronic lymphocytic leukemia; CML: chronic myeloid leukemia;

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome- positive, chronic myeloid leukemia: 24- month

Phase 2 study of subcutane- ous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.

Effi cacy and safety of dasatinib in patients with chronic myeloid leukemia in blast phase whose disease is resistant or intolerant to imatinib: 2-year follow-up data from the START

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in

Methods: We reported a HL patient after treatment that developed the second, third, and fourth malignan- cies (chronic myeloid leukemia, chronic lymphocytic leukemia, and

Imatinib in the treatment of chronic myeloid leukemia in children and adolescents is effective and well tolerated: Report of the Polish Pediatric Study Group for

This study reported a patient who presented with profound hearing loss, visual impairment, in the chronic phase of chronic myeloid leukemia.. After treatment,

ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; ANOVA: Analysis of variance; CLL: Chronic lymphocytic leukemia; CML: Chronic myelogenous leukemia; CRCUS:

A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis

Ph: Philadelphia chromosome; CML: chronic myeloid leukemia; ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; MPAL: mixed‑pheno‑ type acute leukemia; TK: tyrosine

Respons Hematologi Penderita Chronic Myeloid Leukemia Setelah Terapi Imatinib di RSUD DR.. Chronic

In chronic myeloid leukemia (CML) and Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) patients who fail imatinib treatment, BCR-ABL1 mutation profiling by